Integrated Filing — IndAS



General information about company

Scrip Code 500288
NSE Symbol MOREPENLAB
MSEI Symbol NOTLISTED
ISIN INE083A01026
Name of company MOREPEN LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 27-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 27-10-2026   11:30:00
End date and time of board meeting 27-10-2026   13:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 10-02-2026
Indicate Company website link for updated RPT policy of the Company https://morepen.s3.ap-south-1.amazonaws.com/investor/img/pdf/Policy%20on%20Dealings%20with%20Related%20Party%20Transaction%20(1).pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 67,799.85 1,21,903.98
Other income 843.45 1,374.54
Total income 68,643.30 1,23,278.52
2 Expenses
(a) Cost of materials consumed 41,190.55 74,028.60
(b) Purchases of stock-in-trade 108.51 543.23
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (3,029.44) (5,059.93)
(d) Employee benefit expense 7,175.55 12,753.82
(e) Finance costs 510.41 988.26
(f) Depreciation, depletion and amortisation expense 969.85 1,767.79
(f) Other Expenses
1 Power and Fuel 1,319.13 2,599.80
2 Travelling Expenses 666.09 1,098.25
3 Selling and Distribution Expenses 3,941.31 8,248.51
4 Other Expenses 5,426.00 8,729.69
Total other expenses 11,352.53 20,676.25
Total expenses 58,277.96 1,05,698.02
3 Total profit before exceptional items and tax 10,365.34 17,580.50
4 Exceptional items 0.00 0.00
5 Total profit before tax 10,365.34 17,580.50
6 Tax expense
7 Current tax 2,064.67 3,880.00
8 Deferred tax 513.47 513.47
9 Total tax expenses 2,578.14 4,393.47
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 7,787.20 13,187.03
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 7,787.20 13,187.03
17 Other comprehensive income net of taxes 8.07 27.08
18 Total Comprehensive Income for the period 7,795.27 13,214.11
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 10,958.41 10,958.41
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.42 2.41
Diluted earnings (loss) per share from continuing operations 1.42 2.41
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.42 2.41
Diluted earnings (loss) per share from continuing and discontinued operations 1.42 2.41
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 27, 2026. A Limited review of the same has been carried out by the Statutory Auditors. 2. The shareholders of the company approved final dividend of Rs. 0.20 per equity share of the face value of Rs. 2.00 each, in their Annual General meeting held on September 26, 2026, and dividend was paid on October 13, 2026. 3. On October 14, 2026 the company received a favourable order from Hon'ble High Court of Himachal Pradesh, Shimla wherein the SCN issued by the Office of the Commissioner, Central GST & Central Excise Commissionerate, Shimla seeking recovery of Rs.117.94 crores was quashed and disposed of the writ petition. Thereby the company has considered the contingent liability of Rs.317.37 crores (inclusive of recovery amount, interest and penality) as disposed off. 4. The above results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (“Ind AS”) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 5. The Company is engaged in the Pharmaceutical Business Segment.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 33,651.96
Capital work-in-progress 941.63
Investment property 0.00
Goodwill 0.00
Other intangible assets 11,025.69
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 12,447.53
Trade receivables, non-current
Loans, non-current 8.30
Other non-current financial assets
1 Other Financial Assets 663.45
Total of other non-current financial assets 663.45
Total non-current financial assets 13,119.28
Deferred tax assets (net)
Other non-current assets
1 Other non-current assets 14,855.92
Total of other non-current assets 14,855.92
Total non-current assets 73,594.48
2 Current assets
Inventories 21,341.92
Current financial asset
Current investments 441.82
Trade receivables, current 32,902.15
Cash and cash equivalents 13,980.76
Bank balance other than cash and cash equivalents 7,205.57
Loans, current 33.96
Other current financial assets
Total of other current financial assets 1,323.36
Total current financial assets 55,887.62
Current tax assets (net)
Other current assets
1 Other current assets 37,702.77
2 Assets Included in disposal group held for sale 36,181.54
Total of other current assets 73,884.31
Total current assets 1,51,113.85
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 2,24,708.33
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 10,958.41
Other equity 1,25,445.77
Total equity attributable to owners of parent 1,36,404.18
Non controlling interest
Total equity 1,36,404.18
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 12,065.31
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 42.90
2 Lease Liabilities 628.11
Total of other non-current financial liabilities 671.01
Total non-current financial liabilities 12,736.32
Provisions, non-current 3,441.09
Deferred tax liabilities (net) 2,160.92
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 18,338.33
Current liabilities
Current financial liabilities
Borrowings, current 18,338.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 128.38
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 31,084.19
Total Trade payable 31,212.57
Other current financial liabilities
1 Lease Liabilities 493.49
2 Other current financial liabilities 3,700.76
Total of other current financial liabilities 4,194.25
Total current financial liabilities 53,744.82
Other current liabilities 915.47
1 Other current liabilities 915.47
Total of other current liabilities 915.47
Provisions, current 2,108.95
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 56,769.24
3 Liabilities directly associated with assets in disposal group classified as held for sale 13,196.58
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 88,304.15
Total equity and liabilites 2,24,708.33
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Assets Included in disposal group held for sale- Rs. 36181.54 Lakh is shown under the head Other current asset as a result the total current asset is reflecting as Rs. 151113.85 Lakh instead of Rs. 114932.31 Lakh.



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gain on Defined Benefit Plans 12.96 36.19
2 Income tax relating to items that will not be reclassified to profit or loss (4.89) (9.11)
Total Amount of items that will not be reclassified to profit and loss 8.07 27.08
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 8.07 27.08



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 17,580.50
Adjustments for reconcile profit (loss)
Adjustments for finance costs 988.26
Adjustments for decrease (increase) in inventories (4,934.02)
Adjustments for decrease (increase) in trade receivables, current (58.79)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (9,573.08)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 10,135.78
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,767.79
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 36.19
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,637.87)
Net cash flows from (used in) operations 15,942.63
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,402.58
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 11,540.05
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 6.90
Purchase of property, plant and equipment 6,027.89
Proceeds from sales of investment property 0.00
Purchase of investment property 1,374.09
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 1,483.51
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 180.83
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (9,059.42)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 11,621.18
Repayments of borrowings 593.43
Payments of lease liabilities (122.44)
Dividends paid 1,085.78
Interest paid 988.26
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 528.14
Net cash flows from (used in) financing activities 9,604.29
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 12,084.92
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 12,084.92
Cash and cash equivalents cash flow statement at beginning of period 2,299.86
Cash and cash equivalents cash flow statement at end of period 14,384.78





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Morepen Laboratories Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Sale of goods or services 7,500.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 4,759.02 0.00 0.00
2 Morepen Laboratories Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Purchase of goods or services 150.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 0.00 1,187.59 964.62
3 Morepen Laboratories Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Reimbursement of office & rental expense 400.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 160.08 0.00 0.00
4 Morepen Laboratories Limited Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Brand usage expense 350.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 199.57 0.00 0.00
5 Morepen Laboratories Limited Morepen Bio Inc. Wholly Owned Subsidiary Sale of goods or services 20,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 3,092.21 4,165.06 2,741.70
6 Morepen Laboratories Limited Morepen Labs - FZE Wholly Owned Subsidiary Sale of goods or services 1,00,000.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 21,166.02 783.36 6,819.70
7 Morepen Laboratories Limited Morepen RX Limited. Wholly Owned Subsidiary Sale of goods or services 1,500.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 461.38 526.46 1,709.53
8 Morepen Laboratories Limited Morepen RX Limited. Wholly Owned Subsidiary Any other transaction Trade advance returned Transaction is in ordinary course of business & on arm length basis 2,000.00 2,000.00 0.00
9 Morepen Laboratories Limited Morepen RX Limited. Wholly Owned Subsidiary Investment 2,000.00 Transaction is in ordinary course of business & on arm length basis 2,000.00 0.00 0.00
10 Morepen Laboratories Limited Morepen RX Limited. Wholly Owned Subsidiary Any other transaction Reimbursement of office & rental expense 200.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 56.79 0.00 0.00
11 Morepen Laboratories Limited Morepen Device Limited Wholly Owned Subsidiary Sale of goods or services 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 40.32 30.60 28.42
12 Morepen Laboratories Limited Morepen Device Limited Wholly Owned Subsidiary Any other transaction reimbursement of office & rental expense 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 0.25 0.00 0.00
13 Morepen Laboratories Limited Edit 25 Lifestyle Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Purchase of goods or services 150.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 52.29 0.00 9.41
14 Morepen Laboratories Limited Mr. Anubhav Suri Relative of Key Management Personnel Any other transaction Transfer of Equity Shares of Morepen Medipath Ltd, (Subsidiary Company) 16.20 Transaction is not in ordinary course of business & also on arm length basis, therefore, recommended to the board of directors for their approval. 16.20 0.00 0.00
15 Morepen Laboratories Limited Mr. Sushil Suri Chairman & Managing Director Remuneration 1,650.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 238.65 7.75 65.87 Textual Information(1)
16 Morepen Laboratories Limited Mr. Sanjay Suri Managing Director Remuneration 1,400.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 686.33 0.72 28.33 Textual Information(2)
17 Morepen Laboratories Limited Mr. Ajay Kumar Sharma Chief Financial Officer Remuneration 300.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 78.97 6.62 9.84
18 Morepen Laboratories Limited Mr. Vipul Kumar Srivastava Company Secretary Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 40.64 4.25 6.73
19 Morepen Laboratories Limited Mr. Anubhav Suri Relative of Key Management Personnel Remuneration 800.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 579.68 311.43 555.90 Textual Information(3)
20 Morepen Laboratories Limited Mr. Kushal Suri Relative of Key Management Personnel Remuneration 700.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 243.10 7.26 45.24 Textual Information(4)
21 Morepen Laboratories Limited Mr. Rajas Suri Relative of Key Management Personnel Remuneration 140.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 29.98 6.37 7.36
22 Morepen Laboratories Limited Mrs. Mamta Suri Relative of Key Management Personnel Remuneration 120.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 47.03 7.14 7.14
23 Morepen Laboratories Limited Mrs. Sunita Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 28.00 3.15 5.68
24 Morepen Laboratories Limited Mrs. Shalu Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 27.77 1.74 3.58
25 Morepen Laboratories Limited Mrs. Sakshi Suri Relative of Key Management Personnel Remuneration 100.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 28.13 6.18 7.17
26 Morepen Laboratories Limited Mrs. Suhina Suri Relative of Key Management Personnel Remuneration 60.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 22.44 2.93 2.93
27 Morepen Laboratories Limited Mrs. Bavleen Suri Relative of Key Management Personnel Remuneration 60.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 22.44 5.87 5.87
28 Morepen Laboratories Limited Ms.Aanandi Suri Relative of Key Management Personnel Remuneration 60.00 The RPT was reviewed by the Audit Committee, approved by the board of directors and members. 15.01 3.92 2.08
29 Morepen Laboratories Limited Mr. Arjun Suri Relative of Key Management Personnel Remuneration 60.00 The RPT was reviewed by the Audit Committee, approved by the board of directors and members. 15.01 1.68 1.94
30 Morepen Laboratories Limited Mrs. Amita Sharma Relative of Key Management Personnel Remuneration 200.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 66.07 5.53 7.50
31 Morepen Laboratories Limited Morepen Proprietary Drug Research Private Limited. Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Purchase of goods or services 2,500.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 1,655.00 12.62 303.98
32 Morepen Laboratories Limited Groom Town Private Limited. Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Common Services 50.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 2.21 1.07 0.04
33 Morepen Laboratories Limited Quickmed Private Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Sale of goods or services Transaction is in ordinary course of business & on arm length basis and repetitive in nature 10.28 5.23 12.87
34 Morepen RX Limited. Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Sale of goods or services 25.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 2.29 0.00 8.18
35 Morepen RX Limited. Dr. Morepen Limited Entities over which persons i.e., KMP/ relative of KMP having control or significant Influence Any other transaction Common Services 75.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 18.84 0.00 0.00
36 Morepen RX Limited. Mr.Varun Suri Whole-Time Director Remuneration 200.00 Transaction is in ordinary course of business & on arm length basis and repetitive in nature 78.90 4.76 11.57
37 Morepen Laboratories Limited Morepen Labs - FZE Wholly Owned Subsidiary Any other transaction Trade advance returned Transaction is in ordinary course of business & on arm length basis 20.78 15.78 4.78
Total value of transaction during the reporting period 37,961.68



Text Block

Textual Information(1) Remuneration including incentive
Textual Information(2) Remuneration including incentive
Textual Information(3) Remuneration including incentive
Textual Information(4) Remuneration including incentive